VYNE Therapeutics Inc.
USD0.65
+0.00 (+0.39%)
CEO
David T. Domzalski
IPO Date
2018-01-25
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
Open
$0.65
Prev. Close
$0.65
Day Low
$0.65
Day High
$0.66
52W Low
$0.28
52W High
$1.96
Market Cap
$0.01B
Volume
0.01M
| 4,007 |
| $0.60 |
| 2 Apr 2026 | Stuart Iain | CHIEF SCIENTIFIC OFFICER | F-InKind | Disposed | 2,876 | $0.60 |
| 2 Apr 2026 | Harsch Mutya | CHIEF LEGAL OFFICER AND GC | F-InKind | Disposed | 4,007 | $0.60 |
| 2 Apr 2026 | Domzalski David | director, officer: PRESIDENT AND CEO | F-InKind | Disposed | 14,232 | $0.60 |
| 5 Jan 2026 | Domzalski David | director, officer: PRESIDENT AND CEO | F-InKind | Disposed | 12,684 | $0.58 |
| 5 Jan 2026 | Zeronda Tyler | CHIEF FINANCIAL OFFICER | F-InKind | Disposed | 7,858 | $0.58 |
| 5 Jan 2026 | Stuart Iain | CHIEF SCIENTIFIC OFFICER | F-InKind | Disposed | 2,448 | $0.58 |
| 5 Jan 2026 | Harsch Mutya | CHIEF LEGAL OFFICER AND GC | F-InKind | Disposed | 3,579 | $0.58 |
| 15 Dec 2025 | Little Elisabeth Sandoval | director | A-Award | Acquired | 20,000 | $0.38 |